Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

David G. Maloney, MD PhD, John Kuruvilla, MD, Christopher P Fox, MD PhD, Guillaume Cartron, MD PhD, Daniel Li, PhD, Jens Hasskarl, MD, Ashley Bonner, PhD, Yixie Zhang, PhD, Fei Fei Liu, BSc, MBA

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137719

Published: 2020

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Brakke, MS, Stephanie Rhea, BS, Roxana Hicks, BS, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, PhD, Daniel Li, PhD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4022.

https://doi.org/10.1182/blood-2018-99-117493

Published: 2018

Journal Articles

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2018-99-115126

Published: 2018

Journal Articles

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Blood (2018) 132 (Supplement 1): 281.

https://doi.org/10.1182/blood-2018-99-110561

Published: 2018

Journal Articles

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Blood (2018) 132 (Supplement 1): 299.

https://doi.org/10.1182/blood-2018-99-111061

Published: 2018

Journal Articles

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Cameron J. Turtle, MBBS, PhD, Kevin A. Hay, MD FRCPC, MSc, Laila-Aicha Hanafi, PhD, Juliane Gust, MDPhD, W. Conrad Liles, MDPhD, José A. López, MD, Junmei Chen, PhD, Dominic W. Chung, PhD, Mark M Wurfel, MDPhD, Susanna Harju-Baker, PhD, Hasan Ozpolat, MD, Daniel Li, PhD, David Myerson, MDPhD, Luis F. Gonzalez-Cuyar, MD, Cecilia Yeung, MD, Kathleen R. Fink, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD

Blood (2017) 130 (Supplement 1): 805.

https://doi.org/10.1182/blood.V130.Suppl_1.805.805

Published: 2017

Journal Articles

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Mark Heipel, BSc, Jeffrey Smith, BA, William Brown, MAS, Mandana Karimi, MSc, Benhuai Xie, PhD, Daniel Li, PhD, Tina Albertson, MD, Jacob Garcia, MD, Todd Devries, PhD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 2835.

https://doi.org/10.1182/blood.V130.Suppl_1.2835.2835

Published: 2017

Journal Articles

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Tanya Siddiqi, MD, Jeremy S. Abramson, MD MMSc, Daniel Li, PhD, William Brown, MAS, Todd Devries, PhD, Kedar Dave, PhD, Jacob Garcia, MD, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, BS, Andres Forero-Torres, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Claire L Sutherland, PhD

Blood (2017) 130 (Supplement 1): 193.

https://doi.org/10.1182/blood.V130.Suppl_1.193.193

Published: 2017

Journal Articles

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Christina Swanson, PhD, Trevor Do, Samantha Merrigan, Shaparak Lonning, Kim Merriam, Joshua Prentiss, Janani Sridar, Claire L Sutherland, PhD, Benhuai Xie, PhD, Minh Pham, Daniel Li, PhD, Tina Albertson, MD, Howard M Stern, MDPhD, Sharon Moulis, PhD

Blood (2017) 130 (Supplement 1): 194.

https://doi.org/10.1182/blood.V130.Suppl_1.194.194

Published: 2017

Journal Articles

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

David G. Maloney, MD PhD, Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 1552.

https://doi.org/10.1182/blood.V130.Suppl_1.1552.1552

Published: 2017

Journal Articles

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, Jon E. Arnason, MD, Michael Wang, MD, Andres Forero, MD, David G. Maloney, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Daniel Li, PhD, Benhuai Xie, PhD, Tanya Siddiqi, MD

Blood (2017) 130 (Supplement 1): 581.

https://doi.org/10.1182/blood.V130.Suppl_1.581.581

Published: 2017

Journal Articles

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Cameron J Turtle, MBBS, PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G Maloney, MD PhD

Blood (2016) 128 (22): 56.

https://doi.org/10.1182/blood.V128.22.56.56

Published: 2016

Journal Articles

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

Cameron J Turtle, MBBS, PhD, Kevin A Hay, MDFRCPC, MSc, Gust Juliane, MD PhD, Laila-Aicha Hanafi, PhD, Daniel Li, PhD, Colette Chaney, RN, Shelly Heimfeld, PhD, Stanley R Riddell, MD, David G. Maloney, MD PhD

Blood (2016) 128 (22): 1852.

https://doi.org/10.1182/blood.V128.22.1852.1852

Published: 2016

Journal Articles

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Smithers, MS, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Christopher Brown, Stephanie Mgebroff, MS, Catherine Lindgren, Karen Spratt, PhD, Assaf Oron, PhD, Daniel Li, PhD, Marie Bleakley, MDPhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 219.

https://doi.org/10.1182/blood.V128.22.219.219

Published: 2016

Journal Articles

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rebecca Gardner, MD, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Julie Rivers, MD, Juliane Gust, MD, Katherine Tarlock, MD, Todd M Cooper, DO, Navin R. Pinto, MD, Olivia Finney, PhD, Hannah Smithers, MS, Assaf Oron, PhD, Daniel Li, PhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 586.

https://doi.org/10.1182/blood.V128.22.586.586

Published: 2016

Journal Articles

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG ® ) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

Blood (2014) 124 (21): 330.

https://doi.org/10.1182/blood.V124.21.330.330

Published: 2014

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2013) 122 (21): LBA-6.

https://doi.org/10.1182/blood.V122.21.LBA-6.LBA-6

Published: 2013

Journal Articles

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Blood (2013) 122 (21): 85.

https://doi.org/10.1182/blood.V122.21.85.85

Published: 2013

NARROW

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Pharmacokinetic, Pharmacodynamic and Blood Analytes Associated with Clinical Response and Safety in Relapsed/Refractory Aggressive B-NHL Patients Treated with JCAR017

Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017

Predicting Clinical Response and Safety of JCAR017 in B-NHL Patients: Potential Importance of Tumor Microenvironment Biomarkers and CAR T-Cell Tumor Infiltration

Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration

High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort

CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia

Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG ® ) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only